Issue 3, 2012

New potent, short-linker BODIPY-630/650™ labelled fluorescent adenosine receptor agonists

Abstract

New, short-linker BODIPY 630/650™ fluorescent conjugates of the adenosine receptor ligand N-ethylcarboxamido-adenosine (NECA) have been synthesised and pharmacologically evaluated. These novel conjugates confirm that short linkers between the N6-amino group of NECA and the fluorophore are preferred with the best ligand (15b, aminopropyl linker) displaying the greatest potency (Log IC50 (Gi) = −9.31) at the human adenosine A1-receptor. Imaging studies with this compound confirmed it can be employed to selectively label the human adenosine A1-receptor in single living cells, with receptor-associated binding prevented by preincubation with the nonfluorescent antagonist DPCPX.

Graphical abstract: New potent, short-linker BODIPY-630/650™ labelled fluorescent adenosine receptor agonists

Supplementary files

Article information

Article type
Concise Article
Submitted
30 Sep 2011
Accepted
25 Nov 2011
First published
30 Nov 2011

Med. Chem. Commun., 2012,3, 333-338

New potent, short-linker BODIPY-630/650™ labelled fluorescent adenosine receptor agonists

C. L. Dale, S. J. Hill and B. Kellam, Med. Chem. Commun., 2012, 3, 333 DOI: 10.1039/C2MD00247G

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements